These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37366543)

  • 1. Hepatocyte-specific loss of LAP2α protects against diet-induced hepatic steatosis, steatohepatitis, and fibrosis in male mice.
    Upadhyay KK; Choi EK; Foisner R; Omary MB; Brady GF
    Am J Physiol Gastrointest Liver Physiol; 2023 Aug; 325(2):G184-G195. PubMed ID: 37366543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
    J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice.
    Lee SM; Muratalla J; Karimi S; Diaz-Ruiz A; Frutos MD; Guzman G; Ramos-Molina B; Cordoba-Chacon J
    Cell Mol Life Sci; 2023 Jan; 80(2):39. PubMed ID: 36629912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
    He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
    Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
    Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
    Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPS protects the liver against steatosis, cell death, inflammation, and fibrosis in mice with steatohepatitis.
    Yang Y; Liu X; Chen H; Wang P; Yao S; Zhou B; Yin R; Li C; Wu C; Yang X; Yu M
    FEBS J; 2022 Sep; 289(17):5279-5304. PubMed ID: 35285180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization.
    Zhang X; Fan L; Wu J; Xu H; Leung WY; Fu K; Wu J; Liu K; Man K; Yang X; Han J; Ren J; Yu J
    J Hepatol; 2019 Jul; 71(1):163-174. PubMed ID: 30914267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis.
    Kobayashi T; Kanno K; Nguyen PT; Sugiyama A; Kawahara A; Otani Y; Kishikawa N; Ito M; Tazuma S
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2140-2150. PubMed ID: 32365405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte Nuclear Factor 4α Prevents the Steatosis-to-NASH Progression by Regulating p53 and Bile Acid Signaling (in mice).
    Xu Y; Zhu Y; Hu S; Xu Y; Stroup D; Pan X; Bawa FC; Chen S; Gopoju R; Yin L; Zhang Y
    Hepatology; 2021 Jun; 73(6):2251-2265. PubMed ID: 33098092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Notch1 deletion predisposes to diabetes and steatosis via glucose-6-phosphatase and perilipin-5 upregulation.
    Bernsmeier C; Dill MT; Provenzano A; Makowska Z; Krol I; Muscogiuri G; Semela D; Tornillo L; Marra F; Heim MH; Duong FH
    Lab Invest; 2016 Sep; 96(9):972-80. PubMed ID: 27428080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.